IGHID 11424 - A Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection (The VOR VAX Study)

Trial Profile

IGHID 11424 - A Pilot Trial of the Effect of Vorinostat and AGS-004 on Persistent HIV-1 Infection (The VOR VAX Study)

Recruiting
Phase of Trial: Phase I

Latest Information Update: 25 Apr 2018

At a glance

  • Drugs AGS 004 (Primary) ; Vorinostat (Primary)
  • Indications HIV-1 infections
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms VORVAX
  • Most Recent Events

    • 17 Apr 2018 Planned End Date changed from 1 Dec 2019 to 1 Feb 2021.
    • 17 Apr 2018 Planned primary completion date changed from 1 Mar 2018 to 1 Feb 2021.
    • 02 Apr 2018 According to an Argos Therapeutics Inc media release, the company expect to report early results by the end of 2018 or early 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top